Company intelligence / Profile preview

Zambon

Ownership: Private
Employees: ~2900
Development stage: Commercial

Overview

Zambon has commercial products for Parkinson's Disease, respiratory conditions, pain management, and urological conditions. Since 2015, more than 90,000 patients have benefited from their innovative molecule for Parkinson's disease. They have recently entered into licensing agreements for new formulations including IPX203 for Parkinson's Disease.

Therapeutic areas: PulmonologyNeurologyInfectious Diseases
Modalities: Small moleculespharmaceuticals
Industry: Pharma

Drug pipeline

9 assets

safinamide

Approved

8 more assets in the full pipeline.

Request access →

Partnerships

Aquestive TherapeuticsAmneal Pharmaceuticals

Beyond the preview

Go deeper on Zambon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zambon.

Explore the full profile